Drug Profile
Research programme: checkpoint kinase 1 inhibitors - Seagen/Sentinel
Alternative Names: CASC-578; S024; S070; S081; S091; S158; S209Latest Information Update: 18 Dec 2023
Price :
$50
*
At a glance
- Originator Sentinel Oncology
- Developer Seagen; Sentinel Oncology
- Class Small molecules
- Mechanism of Action Checkpoint kinase 1 inhibitors; DNA repair inhibitors; Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer